The latest industry report published by Credence Research, Inc. “Global ADME Toxicology Testing industry – Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016 – 2022,” the ADME toxicology testing industry was valued at USD 6,986.2 Mn in 2015, and is expected to reach USD 14,319.9 Mn by 2022, expanding at a CAGR of 10.6% from 2016 to 2022.
ADME is the abbreviation for absorption distribution, metabolism and elimination, a pharmacology and pharmacokinetics term that describes the disposition of a drug or compound inside the human body. ADME comprises set of four processes that develop the performance of a drug on human tissue and ADME toxicology testing is applied for the development of a new drug.
Browse the full report ADME Toxicology Testing industry – Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016 – 2022 report at http://www.credenceresearch.com/report/adme-toxicology-testing-market
ADME toxicology facilitated pharmaceutical manufacturing company to minimize their drug discovery time, testing complications, and to reduce the cost of drug development. The growing application of ADME toxicology testing by pharmaceuticals and biotechnology companies is assisting the industry growth of the ADME toxicology testing industry. One of the key factors responsible for late stage drug failures is the inability of drug candidates to imitate in humans the safety profile witnessed in animal models. Before introduction and acceptance of ADME toxicology testing, drug development process included toxicity and efficacy testing in in-vivo environment which was responsible for late stage failure of drugs in human body due to anatomical and genetic differences between animals and humans. To overcome this barrier of drug failure manufacturers across the globe opted for ADME toxicity testing in early drug developmental phases of pre-clinical trials. Increasing adoption of ADME toxicity testing as cost and time curbing tool is further expected to drive growth of this industry. Introduction of technologically advanced computer based testing models are additionally fuelling growth of this industry. According to industry stakeholders, recently pre-clinical ADME toxicology testing is emerging to take on a new application in the drug-discovery venture capital (VC) industry’s financial decision that corresponds in importance and scope to its established role in the scientific decisions of drug discovery firms.
Industry Competition Assessment
The ADME toxicology testing industry is observed as the most diversified and competitive industry comprising large number of players. The industry is dominated by several players, depending on their major competencies. The key players in this industry are Cellartis AB, Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Thermo Fisher Scientific, Inc., Caliper Life Sciences, Inc., Promega Corporation, Cyprotex PLC, Beckman Coulter, Inc., Optivia Biotechnology, Inc., Accelrys, Inc., Molecular Discovery Ltd., MultiCASE, Inc., Xceleron, Inc., ACEA Biosciences, Inc., Albany Molecular Research, Inc., and CeeTox, Inc.
Key industry Movements
Rising application of ADME toxicology testing by pharmaceuticals and biotechnology companies
Growing concerns over application of animals in clinical trials
Increase in demand of cell-based assays in drug discovery
Escalating adoption of ADME toxicity testing as cost and time curbing tool
Request Free Sample: http://www.credenceresearch.com/sample-request/57834
Credence Research is a worldwide industry research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.
Who we are
Credence Research is a worldwide firm, containing more than 15 research consultants and almost 100 research and information professionals.
Our customers mirror our worldwide nature. Around 45% are in Europe, 30% in the Americas, 13% in Asia Pacific and 12% in the Middle East and Africa.
Our firm is intended to work as one. We are a solitary global research organization united by a solid arrangement of qualities, concentrated on customer effect.
Name: Chris Smith
Designation: Global Sales Manager